Omeros Corporation (OMER) Stock Score, Valuation & Financial Research

Omeros Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for OMER

Omeros Corporation does not currently have a complete Wall Street Score. The stored market price is USD 19.87. These figures are a research snapshot, not a buy or sell recommendation.

What Omeros Corporation does

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Omeros Corporation is a commercial-stage biotechnology company that generates revenue primarily through the commercialization of its pharmaceutical products. The company focuses on discovering and developing first-in-class protein and small-molecule therapeutics for complement-mediated diseases, cancers, and addictive or compulsive disorders.

Products and services

The company's primary commercial product is OMIDRIA (phenylephrine and ketorolac injection) 1%/0.3%, which is used during cataract surgery or intraocular lens replacement to maintain pupil size and reduce postoperative pain.

Brands and product families

OMIDRIA — FDA-approved product for use during cataract surgery or intraocular lens replacement. Source

Customer types

Hospitals and Ambulatory Surgery Centers.

Suppliers, materials and equipment

Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its pharmaceutical products and clinical trial materials. Source

Business strengths to evaluate

Proprietary platform for complement-mediated disease therapeutics Source

Business risks and research considerations

Significant history of operating losses and accumulated deficit Source
Dependence on the commercial success of OMIDRIA Source
Risks associated with clinical trial outcomes and regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

OMER financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 19.87
Market capitalization:: 1.44B (currency not supplied)
Revenue:: USD 38.42M
Net income:: USD 124.83M
Free cash flow:: USD -116.16M
Cash:: USD 1.99M
Total debt:: USD 83.77M
EPS:: USD 1.91
P/E ratio:: 10.4x

What stands out

Free cash flow is USD -116.16M, negative for the stored period.
The balance sheet shows USD 1.99M of cash versus USD 83.77M of total debt, with debt exceeding cash on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Free cash flow is -302.3% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
Net income equals 324.9% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
Debt exceeds cash by USD 81.79M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for OMER

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can OMER fund negative free cash flow using its current cash position before it may need more debt or new shares?
Is OMER's debt load manageable relative to cash generation, interest costs and upcoming maturities?
What does the current fundamental change risk warning mean for the reliability or interpretation of OMER's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research OMER

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.